“So you give it to a person who already had the real thing. That is like giving Warren Buffett a hundred dollar bill.” — Joseph Whitfield, PA-C, of Corpus Christi, Texas, commenting on giving the COVID-19 vaccine to those who already had the virus.
“We treat patients at the bedside. We don’t have the ivory tower syndrome where you tell people what to do though you have no idea what you’re doing.” — Paul Marik, MD, of Eastern Virginia Medical School, whose group Front Line COVID-19 Critical Care Alliance, has raised eyebrows while championing ivermectin for COVID-19.
“The FDA has had no say about what the test should measure, what are healthy and unhealthy levels, or how to ensure accuracy and predictability.” — Alzheimer’s Association chief science officer Maria Carrillo, PhD, commenting on the first blood test for Alzheimer’s disease to enter the market.
“We were completely surprised.” — Avindra Nath, MD, clinical director at the National Institute of Neurological Disorders and Stroke (NINDS), discussing high-resolution MRI findings in autopsied brain tissue of people who had COVID-19.
“The benefit gained was just profound.” — Roy Herbst, MD, PhD, of Yale Cancer Center, discussing data on osimertinib (Tagrisso) in lung cancer patients with brain metastases.
“If the virus hits before your first meal of the day when acid levels are low, or if you’re taking a PPI or get a particularly large inoculum of virus, enough can get through to make it past.” — Brennan Spiegel, MD, of Cedars-Sinai Medical Center in Los Angeles, commenting on how COVID-19 can infiltrate the digestive system.